BridgeBio Pharma Inc. (NASDAQ:BBIO) concluded the trading at $10.71 on Wednesday, September 21 with a fall of -6.95% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $11.51 and 5Y monthly beta was reading 0.79 with its price kept floating in the range of $10.70 and $11.65 on the day. Considering stock’s 52-week price range provides that BBIO hit a high price of $53.57 and saw its price falling to a low level of $4.98 during that period. Over a period of past 1-month, stock came adding 4.49% in its value.
With its current market valuation of $1.70 billion, BridgeBio Pharma Inc. is set to declare its quarterly results on Feb 23, 2022 – Feb 28, 2022. Analysts are in estimates of -$0.63 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$3.57 for 2022 with estimates of that growing to -$3.17 in next year. These estimates are suggesting current year growth of 8.50% for EPS and 11.20% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $16.07 million. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $46.71 million in 2022, which will be -33.00% less from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review BBIO stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 50% Buy for it.
According to ratings assigned by 9 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending BridgeBio Pharma Inc. (BBIO) as a Hold, while 8 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 1, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the BBIO stock which is currently positioned at 0. It further provides that stock’s current price level is -2.65% away from its 20-day simple moving average and is 2.39% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 48.40 while volatility remained at 7.26% over the past week which changes to 8.45% when measuring it over the past month. Average true range or ATR is currently at 0.90.
Having a second look at BridgeBio Pharma Inc. (NASDAQ:BBIO) provides that stock’s average daily trading volume for 3 months was 2.24 million, while it jumped to 2.58 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 146.69 million.
The percentage of outstanding shares held by the insiders is 5.10% while it is 96.00% for the institutional holders. The figures also indicate that as of Jul 14, 2022, number of stock’s short shares was 20.9 million which implies a short ratio of 10.01. This shows down a 14.15% of Short Interest in company’s outstanding shares on the day. In July the standing of shares short improved as it was 21.02 million in the previous month. Subtraction of -35.79% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.